QQQ   431.53 (+0.11%)
AAPL   169.37 (-1.92%)
MSFT   416.01 (+0.57%)
META   501.72 (+0.30%)
GOOGL   154.95 (+0.06%)
AMZN   183.77 (+0.08%)
TSLA   156.21 (-3.26%)
NVDA   875.50 (+1.80%)
AMD   163.23 (+1.82%)
NIO   3.86 (-0.77%)
BABA   69.96 (-0.93%)
T   16.02 (-1.35%)
F   12.14 (-0.74%)
MU   121.43 (+0.05%)
GE   156.05 (+1.53%)
CGC   6.82 (-2.29%)
DIS   113.93 (+0.87%)
AMC   2.76 (+11.74%)
PFE   25.79 (-0.46%)
PYPL   63.73 (+0.35%)
XOM   118.65 (-0.86%)
QQQ   431.53 (+0.11%)
AAPL   169.37 (-1.92%)
MSFT   416.01 (+0.57%)
META   501.72 (+0.30%)
GOOGL   154.95 (+0.06%)
AMZN   183.77 (+0.08%)
TSLA   156.21 (-3.26%)
NVDA   875.50 (+1.80%)
AMD   163.23 (+1.82%)
NIO   3.86 (-0.77%)
BABA   69.96 (-0.93%)
T   16.02 (-1.35%)
F   12.14 (-0.74%)
MU   121.43 (+0.05%)
GE   156.05 (+1.53%)
CGC   6.82 (-2.29%)
DIS   113.93 (+0.87%)
AMC   2.76 (+11.74%)
PFE   25.79 (-0.46%)
PYPL   63.73 (+0.35%)
XOM   118.65 (-0.86%)
QQQ   431.53 (+0.11%)
AAPL   169.37 (-1.92%)
MSFT   416.01 (+0.57%)
META   501.72 (+0.30%)
GOOGL   154.95 (+0.06%)
AMZN   183.77 (+0.08%)
TSLA   156.21 (-3.26%)
NVDA   875.50 (+1.80%)
AMD   163.23 (+1.82%)
NIO   3.86 (-0.77%)
BABA   69.96 (-0.93%)
T   16.02 (-1.35%)
F   12.14 (-0.74%)
MU   121.43 (+0.05%)
GE   156.05 (+1.53%)
CGC   6.82 (-2.29%)
DIS   113.93 (+0.87%)
AMC   2.76 (+11.74%)
PFE   25.79 (-0.46%)
PYPL   63.73 (+0.35%)
XOM   118.65 (-0.86%)
QQQ   431.53 (+0.11%)
AAPL   169.37 (-1.92%)
MSFT   416.01 (+0.57%)
META   501.72 (+0.30%)
GOOGL   154.95 (+0.06%)
AMZN   183.77 (+0.08%)
TSLA   156.21 (-3.26%)
NVDA   875.50 (+1.80%)
AMD   163.23 (+1.82%)
NIO   3.86 (-0.77%)
BABA   69.96 (-0.93%)
T   16.02 (-1.35%)
F   12.14 (-0.74%)
MU   121.43 (+0.05%)
GE   156.05 (+1.53%)
CGC   6.82 (-2.29%)
DIS   113.93 (+0.87%)
AMC   2.76 (+11.74%)
PFE   25.79 (-0.46%)
PYPL   63.73 (+0.35%)
XOM   118.65 (-0.86%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accuray Incorporated stock logo
ARAY
Accuray
$2.24
-3.0%
$2.57
$2.22
$4.30
$222.14M1.44433,252 shs214,000 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$10.06
-8.5%
$9.96
$3.89
$14.75
$235.10M1.11527,859 shs603,247 shs
Iradimed Corporation stock logo
IRMD
Iradimed
$41.16
+0.7%
$43.50
$36.12
$51.04
$521.09M0.8252,124 shs14,903 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$7.70
-1.5%
$8.96
$3.78
$13.62
$425.19M1.67184,893 shs72,515 shs
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$9.54
$8.53
$5.48
$14.23
$354.92M1.31822,700 shs1.16 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accuray Incorporated stock logo
ARAY
Accuray
+1.32%-3.75%-11.49%-16.91%-23.00%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-0.36%-3.09%+2.38%-89.84%-91.05%
Iradimed Corporation stock logo
IRMD
Iradimed
-0.99%-3.31%-7.66%-8.73%+3.62%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
+8.31%+3.99%-24.15%-4.98%+35.29%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Accuray Incorporated stock logo
ARAY
Accuray
3.6485 of 5 stars
3.51.00.04.62.11.70.6
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.4071 of 5 stars
3.32.00.04.62.00.00.6
Iradimed Corporation stock logo
IRMD
Iradimed
4.9038 of 5 stars
3.54.01.74.43.83.31.3
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
0.6298 of 5 stars
0.00.00.04.22.73.30.0
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accuray Incorporated stock logo
ARAY
Accuray
3.00
Buy$8.25268.30% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.67
Moderate Buy$96.00854.27% Upside
Iradimed Corporation stock logo
IRMD
Iradimed
3.00
Buy$60.0045.77% Upside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/A

Current Analyst Ratings

Latest INO, PLSE, IRMD, SPNE, and ARAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Iradimed Corporation stock logo
IRMD
Iradimed
Singular Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/7/2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
1/25/2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$48.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accuray Incorporated stock logo
ARAY
Accuray
$447.61M0.50N/AN/A$0.56 per share4.00
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$830K283.26N/AN/A$5.16 per share1.95
Iradimed Corporation stock logo
IRMD
Iradimed
$65.56M7.95$1.42 per share28.99$5.66 per share7.27
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K607.42N/AN/A$0.81 per share9.51
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$191.45M1.85N/AN/A$8.57 per share1.11

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accuray Incorporated stock logo
ARAY
Accuray
-$9.28M-$0.15N/A16.00N/A-3.25%-28.11%-3.05%4/24/2024 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$7.56N/AN/AN/A-16,238.91%-79.86%-57.71%5/8/2024 (Estimated)
Iradimed Corporation stock logo
IRMD
Iradimed
$17.19M$1.3630.26N/A26.22%24.62%20.43%5/2/2024 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%5/9/2024 (Estimated)
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
-$54.35M-$1.77N/AN/AN/A-28.22%-22.16%-17.09%N/A

Latest INO, PLSE, IRMD, SPNE, and ARAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/8/2024Q4 2023
Iradimed Corporation stock logo
IRMD
Iradimed
$0.37$0.36-$0.01$0.36N/A$17.45 million
1/31/202412/31/2023
Accuray Incorporated stock logo
ARAY
Accuray
-$0.05-$0.10-$0.05-$0.10$107.11 million$107.24 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Accuray Incorporated stock logo
ARAY
Accuray
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Iradimed Corporation stock logo
IRMD
Iradimed
$0.601.46%N/A44.12%N/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accuray Incorporated stock logo
ARAY
Accuray
3.53
1.58
0.84
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.60
3.60
Iradimed Corporation stock logo
IRMD
Iradimed
N/A
4.65
3.87
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.09
3.18
1.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Accuray Incorporated stock logo
ARAY
Accuray
64.08%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Iradimed Corporation stock logo
IRMD
Iradimed
92.34%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
70.81%

Insider Ownership

CompanyInsider Ownership
Accuray Incorporated stock logo
ARAY
Accuray
3.78%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.90%
Iradimed Corporation stock logo
IRMD
Iradimed
42.60%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
69.70%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
9.32%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Accuray Incorporated stock logo
ARAY
Accuray
1,02499.17 million95.42 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
12223.37 million22.93 millionOptionable
Iradimed Corporation stock logo
IRMD
Iradimed
14812.66 million7.27 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.22 million16.73 millionOptionable
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
52337.20 million33.74 millionOptionable

INO, PLSE, IRMD, SPNE, and ARAY Headlines

SourceHeadline
Orthobond Received FDA De Novo Approval for Antibacterial TechnologyOrthobond Received FDA De Novo Approval for Antibacterial Technology
jdsupra.com - April 16 at 1:18 PM
Theradaptive Strengthens Executive Team with Hire of Frank Vizesi as Chief Scientific OfficerTheradaptive Strengthens Executive Team with Hire of Frank Vizesi as Chief Scientific Officer
finance.yahoo.com - April 16 at 1:18 PM
Orthobond wins FDA de novo approval for antimicrobial technology that could have vast device applicationsOrthobond wins FDA de novo approval for antimicrobial technology that could have vast device applications
massdevice.com - April 8 at 2:26 PM
SeaSpine, Orthofix name chief enabling technologies officerSeaSpine, Orthofix name chief enabling technologies officer
beckersspine.com - April 1 at 2:54 PM
Surgeons Use Apple VR Headset During Spinal OperationSurgeons Use Apple VR Headset During Spinal Operation
futurism.com - March 18 at 8:03 AM
Lucas Vitale Joins Orthofix as Chief People and Business Operations OfficerLucas Vitale Joins Orthofix as Chief People and Business Operations Officer
stockhouse.com - March 18 at 8:03 AM
Nikki Haley says Susan Collins showed a ‘steel spine’ for backing her over Trump in GOP primaryNikki Haley says Susan Collins showed a ‘steel spine’ for backing her over Trump in GOP primary
usatoday.com - March 6 at 7:11 PM
Bone Grafts and Substitutes Market Ascends to a Robust US$6.3 Billion Valuation by 2032Bone Grafts and Substitutes Market Ascends to a Robust US$6.3 Billion Valuation by 2032
pharmiweb.com - February 5 at 2:06 AM
Spine Biologics Market Revolution: Redefining Spine Treatment ApproachesSpine Biologics Market Revolution: Redefining Spine Treatment Approaches
pharmiweb.com - December 29 at 1:03 PM
OHSU completes 1st awake spine surgeryOHSU completes 1st awake spine surgery
beckersasc.com - December 22 at 11:40 PM
Prosecutors investigate spinal implantProsecutors investigate spinal implant
bbc.com - December 20 at 12:58 AM
Medical Moment: Alternative to spinal fusion helping some patientsMedical Moment: Alternative to spinal fusion helping some patients
wndu.com - December 17 at 11:59 PM
Epidural Steroid Injections Ineffective for Lumbar Spinal StenosisEpidural Steroid Injections Ineffective for Lumbar Spinal Stenosis
medscape.com - December 16 at 6:56 PM
10 spine, orthopedic patent disputes to know10 spine, orthopedic patent disputes to know
beckersspine.com - December 15 at 7:34 PM
Polyether Ether Ketone Interbody Devices Market on the Verge of Surging to US$ 4525 Million by 2033-FMI ProjectionPolyether Ether Ketone Interbody Devices Market on the Verge of Surging to US$ 4525 Million by 2033-FMI Projection
fmiblog.com - December 7 at 10:26 AM
Orthobiologics Market size to grow by USD 2.64 billion from 2022-2027, North America to account for 41% of market growth - TechnavioOrthobiologics Market size to grow by USD 2.64 billion from 2022-2027, North America to account for 41% of market growth - Technavio
finance.yahoo.com - December 1 at 7:42 PM
How well-positioned is Orthofix for 2024?How well-positioned is Orthofix for 2024?
beckersspine.com - December 1 at 2:42 PM
Back Pain In Winter Home Remedies: Top 10 Essential Tips to Keep You Spine Healthy While SleepingBack Pain In Winter Home Remedies: Top 10 Essential Tips to Keep You Spine Healthy While Sleeping
thehealthsite.com - November 28 at 12:19 PM
Orthofix has a new CEOOrthofix has a new CEO
massdevice.com - November 28 at 12:19 PM
Virginia running back undergoes spinal surgery after leaving game on stretcherVirginia running back undergoes spinal surgery after leaving game on stretcher
foxnews.com - November 14 at 6:24 PM
Chinese scientists claim anti-ageing breakthrough with spinal cord discoveryChinese scientists claim anti-ageing breakthrough with spinal cord discovery
scmp.com - November 9 at 2:59 PM
Orthofix Reports Third Quarter 2023 ResultsOrthofix Reports Third Quarter 2023 Results
finance.yahoo.com - November 8 at 7:04 PM
Spine-tingling terror in UKs most haunted city - locals strangled by ghosts and boy lost in shadowsSpine-tingling terror in UK's 'most haunted' city - 'locals strangled by ghosts and boy lost in shadows'
mirror.co.uk - November 8 at 2:03 PM
Biomechanics of Minor Automobile Accidents: Treatment Implications for Associated Chronic Spine SymptomsBiomechanics of Minor Automobile Accidents: Treatment Implications for Associated Chronic Spine Symptoms
medscape.com - October 31 at 7:11 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Accuray logo

Accuray

NASDAQ:ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

NASDAQ:INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Iradimed logo

Iradimed

NASDAQ:IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
SeaSpine logo

SeaSpine

NASDAQ:SPNE
As of January 4, 2023, SeaSpine Holdings Corporation was acquired by Orthofix Medical Inc. SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.